Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Kadimastem and iTolerance achieve a significant milestone in the development of a potential cure for Type 1 Diabetes through successful completion of a pre-IND meeting with the FDA. Learn more about the innovative approach and collaborative efforts towards revolutionizing diabetes treatment.
This news signifies a potentially transformative step in diabetes treatment, paving the way towards the potential development of iTOL-100 and requesting regulatory approvals for commercialization of a potential cure for type 1 diabetes.
